Oncopeptides (STO: ONCO)

Last close As at 02/03/2026

SEK1.62

−0.08 (−4.71%)

Market capitalisation

SEK660m

Oncopeptides is a Swedish biotech company developing peptide-drug conjugates for the treatment of hematological cancers, with a focus on relapsed or refractory multiple myeloma.

Latest Insights

Healthcare | Quickview

Oncopeptides — Targeted oncology with commercial momentum

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Sofia Heigis

    CEO

  • Henrik Bergentoft

    CFO